SCHEMBL2252182

SCHEMBL2252182

CN(C)C=C(C#N)C(=O)c1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
KMT2A Q03164 2/20 0.56
KDM4E B2RXH2 1/20 0.56
PKM P14618 1/20 0.56
MAPK1 P28482 1/20 0.56
EGFR P00533 1/20 0.54
ERBB2 P04626 1/20 0.54
CYP11B1 P15538 6/20 0.52
RAB9A P51151 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
CYP11B2 P19099 4/20 0.48
POLB P06746 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 1/20 0.46
MEN1 O00255 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2252180 1.00 ALDH1A1 (0.56) ALDH1A1KMT2AKDM4EPKMMAPK1
SCHEMBL2252176 1.00 ALDH1A1 (0.56) ALDH1A1KMT2AKDM4EPKMMAPK1
SCHEMBL2253256 0.83 ALDH1A1 (0.64) ALDH1A1KMT2ACYP11B1RAB9AL3MBTL1
SCHEMBL2253263 0.83 ALDH1A1 (0.64) ALDH1A1KMT2ACYP11B1RAB9AL3MBTL1
SCHEMBL2253260 0.83 ALDH1A1 (0.64) ALDH1A1KMT2ACYP11B1RAB9AL3MBTL1
SCHEMBL4468681 0.82 POLB (0.55) ALDH1A1CYP11B1RAB9AL3MBTL1CYP11B2
SCHEMBL4468677 0.82 POLB (0.55) ALDH1A1CYP11B1RAB9AL3MBTL1CYP11B2
SCHEMBL9190963 0.82 POLB (0.55) ALDH1A1CYP11B1RAB9AL3MBTL1CYP11B2
SCHEMBL2252910 0.82 POLB (0.55) ALDH1A1KMT2ACYP11B1RAB9AL3MBTL1
SCHEMBL2252906 0.82 POLB (0.55) ALDH1A1KMT2ACYP11B1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2531503-A1 GAMMA SECRETASE MODULATERS F. Hoffmann-La Roche AG (CH) 2012-12-12 EP disclosed
WO-2011092272-A1 GAMMA SECRETASE MODULATERS F. HOFFMANN-LA ROCHE AG (CH) 2011-08-04 WO disclosed
US-20110190269-A1 GAMMA SECRETASE MODULATORS HOFFMANN-LA ROCHE, INC. 2011-08-04 US disclosed
US-5663119-A FOR USE IN AGRICULTURE RHONE-POULENC AGROCHIMIE (FR) 1997-09-02 US disclosed
US-5607936-A USEFUL IN TREATMENT OF RESPIRATORY DISEASES MERCK & CO., INC. (US) 1997-03-04 US disclosed
US-5523280-A TREATING PLANT DISEASES RHONE-POULENC AGROCHIMIE (FR) 1996-06-04 US disclosed
WO-1996010568-A1 SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS MERCK & CO., INC. (US) 1996-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190269-A1 GAMMA SECRETASE MODULATORS BACE1, APH1A, APH1B ALDH1A1 2136/4885KMT2A 1831/4885KDM4E 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.